CAG and GGN Repeat Length Polymorphisms of Androgen Receptor Gene in Women with Breast Cancer: A Case-Control Study from South India


Aim: The Androgen Receptor (AR) is a ligand-dependent transcriptional activator and the AR gene contains a highly polymorphic trinucleotide repeat CAG and GGN in the first exon. Given the lack of information AR-CAG and GGN repeat polymorphism and its potential correlation with breast cancer in South Indian women, we conducted a case-control study to observe the effects of CAG & GGN repeat length polymorphism and risk of breast cancer. Methods: Polymorphisms for AR-CAG and GGN repeat length was detected by Gene Scan analysis in the genomic DNA from cases with breast cancer and controls. Results: Association between AR genotype was calculated by categorising alleles as short (S) and long (L) and taking median value as the cut-off. LL genotype of CAG repeat was found to be associated with breast cancer (OR, 4.58; 95% CI, 10.61-1.98; p—0.0004). GGN repeat having ≥21 was found in most of the cases and none of the cases showed 20 repeats thus indicate that alleles having homozygous repeat 20 may be protective towards breast cancer. Also, SS genotype was observed in 56.84% of cases and in 73.03% of controls (OR, 0.48; 95% CI, 0.26-0.89; p value, 0.02). Conclusion: Our results indicate that longer CAG and GGN repeat may be associated with breast cancer whereas, the shorter GGN repeat length genotype of AR are protective.

Share and Cite:

D. Tosh, B. Panda, T. Nageswar Rao, A. Babu, V. Satti, D. Raghnadharao, L. Singh and L. Rao, "CAG and GGN Repeat Length Polymorphisms of Androgen Receptor Gene in Women with Breast Cancer: A Case-Control Study from South India," Journal of Cancer Therapy, Vol. 3 No. 5A, 2012, pp. 741-748. doi: 10.4236/jct.2012.325093.

Conflicts of Interest

The authors declare no conflicts of interest.


[1] M. Ganapati, “India Has Some of the Highest Cancer Rates in the World,” British Medical Journal, Vol. 330, No. 7485, 2005, p. 215. doi:10.1136/bmj.330.7485.215-c
[2] E. Deutsch, L. Maggiorella, P. Eschwege, J. Bourhis, J. C. Soria and B. Abdulkarim, “Environmental, Genetic and Molecular Features of Prostate Cancer,” The Lancet Oncology, Vol. 5, No. 5, 2004, pp. 303-313. doi:10.1016/S1470-2045(04)01468-8
[3] J. F. Dorgan, C. Longcope, H. E. Stephenson, Jr., R. T. Falk, R. Miller, C. Franz, L. Kahle, W. S. Campbell, J. A. Tangrea and A. Schatzkin, “Serum Sex Hormone Levels Are Related to Breast Cancer Risk in Postmenopausal Women,” Environmental Health Perspectives, Vol. 105, Suppl. 3, 1997, pp. 583-585.
[4] T. S. Gao, M. Marcelli and M. J. McPhaul, “Transcriptional Activation and Transient Expression of the Human Androgen Receptor,” The Journal of Steroid Biochemistry and Molecular Biology, Vol. 59, No. 1, 1996, pp. 9-20. doi:10.1016/S0960-0760(96)00097-0
[5] A. González, D. F. Javier, G. Rodriguez, B. Brito, M. A. Rodríguez, A. Cabrera, J. C. Díaz-hico, R. Reyes, A. Aguirre-Jaime and B. N. Díaz-Chico, “Increased Risk of Breast Cancer in Women Bearing a Combination of Large CAG and GGN Repeats in The Exon 1 of the Androgen Receptor Gene,” European Journal of Cancer, Vol. 43, No. 16, 2007, pp. 2373-2380. doi:10.1016/j.ejca.2007.07.001
[6] B. Nicol′as D′iaz-Chico, F. Germ′an Rodr′iguez, A. Gonz′alez, R. Ram′irez, C. Bilbao, A. C. de Le′on, A. A. Jaime, R. Chirino, D. Navarro and J. C. D′iaz-Chico, “Androgens and Androgen Receptors in Breast Cancer,” Journal of Steroid Biochemistry & Molecular Biology, Vol. 105, No. 1-5, 2007, pp. 1-15.
[7] S. N. Birrell, R. E. Hall and W. D. Tilley, “Role of the Androgen Receptor in Human Breast Cancer,” Journal of Mammary Gland Biology and Neoplasia, Vol. 3, No. 1, 1998, pp. 95-103. doi:10.1023/A:1018730519839
[8] M. Brys, “Androgens and Androgen Receptor: Do They Play a Role in Breast Cancer?” Medical Science Monitor, Vol. 6, No. 2, 2000, pp. 433-438.
[9] D. J. Liao and R. B. Dickson, “Roles of Androgens in the Development, Growth, and Carcinogenesis of the Mammary Gland,” The Journal of Steroid Biochemistry and Molecular Biology, Vol. 80, No. 2, 2002, pp. 175-189. doi:10.1016/S0960-0760(01)00185-6
[10] M. Langer, E. Kubista, M. Schemper and J. Spona, “Androgen Receptors, Serum Androgen Levels and Survival of Breast Cancer Patients,” Archives of Gynecology and Obstetrics, Vol. 247, No. 4, 1990, pp. 203-209. doi:10.1007/BF02389545
[11] J. B. Adams, “Adrenal Androgens and Human Breast Cancer: A New Appraisal,” Treat Breast Cancer Research and Treatment, Vol. 51, No. 2, 1998, pp. 183-188. doi:10.1023/A:1006050720900
[12] L. Bernstein and R. K. Ross, “Endogenous Hormones and Breast Cancer Risk,” Epidemiologic Reviews, Vol. 15, No. 1, 1993, pp. 48-65.
[13] H. C. Shen and G. A. Coetzee, “The Androgen Receptor: Unlocking the Secrets of Its Unique Transactivation Domain,” Vitamins & Hormones, Vol. 71, 2005, pp. 301-319. doi:10.1016/S0083-6729(05)71010-4
[14] D. Navarro, O. P. Luzardo, L. Fernandez, N. Chesa and B. N. Diaz-Chico, “Transition to Androgen-Independence in Prostate Cancer,” The Journal of Steroid Biochemistry and Molecular Biology, Vol. 81, No. 3, 2002, pp. 191-201. doi:10.1016/S0960-0760(02)00064-X
[15] J. Beilin, E. M. Ball, J. M. Favaloro and J. D. Zajac, “Effect of the Androgen Receptor CAG Repeat Polymorphism on Transcriptional Activity: Specificity in Prostate and Non-Prostate Cell Lines,” Journal of Molecular Endocrinology, Vol. 25, No. 1, 2000, pp. 85-96. doi:10.1677/jme.0.0250085
[16] I. Knoke, A. Allera and P. Wieacker, “Significance of the CAG Repeat Length in the Androgen Receptor Gene (AR) for the Transactivation Function of an M780I Mutant AR,” Human Genetics, Vol. 104, No. 3, 1999, pp. 257-261. doi:10.1007/s004390050945
[17] S. P. Huang, Y. H. Chou, W. S. Chang, et al., “Androgen Receptor Gene Polymorphism and Prostate Cancer in Taiwan,” Journal of the Formosan Medical Association, Vol. 102, No. 10, 2003, pp. 680-686.
[18] E. Esteban, N. Rodon, M. Via, E. Gonz′alez-Perez, J. Santamaria, J. M. Dugoujon, F. E. Chennawi, M. Melhaoui, M. Cherkaoui, G. Vona, N. Harich and P. Moral, “Androgen Receptor CAG and GGC Polymorphisms in Mediterraneans: Repeat Dynamics and Population Relationships,” Journal of Human Genetics, Vol. 51, No. 2, 2006, pp. 129-136. doi:10.1007/s10038-005-0336-7
[19] S. M. Gilbert, M. C. Benson and J. M. McKiernan, “Linkage Disequilibrium between the Androgen Receptor Gene CAG and GGC Repeats in the African-American Population,” Current Urology Reports, Vol. 3, No. 3, 2002, pp. 189-193. doi:10.1007/s11934-002-0063-y
[20] H. F. Sleddens, B. A. Oostra, A. O. Brinkmann and J. Trapman, “Trinucleotide (GGN) Repeat Polymorphism in the Human Androgen Receptor (AR) Gene,” Human Molecular Genetics, Vol. 2, No. 4, 1993, p. 493. doi:10.1093/hmg/2.4.493
[21] G. Rodriguez, C. Bilbao, R. Ramirez, O. Falcon, L. Leon, R. Chirino, O. Falcon, Jr., B. P. Diaz, J. F. Rivero, M. Perucho, B. N. Diaz-Chico and J. C. Diaz-Chico, “Alleles with Short CAG and GGN Repeats in the Androgen Receptor Gene Are Associated with Benign Endometrial Cancer,” International Journal of Cancer, Vol. 118, No. 6, 2006, pp. 1420-1425. doi:10.1002/ijc.21516
[22] M. P. Zeegers, L. A. Kiemeney, A. M. Nieder and H. R. Ostrer, “How Strong Is the Association between CAG and GGN Repeat Length Polymorphisms in the Androgen Receptor Gene and Prostate Cancer Risk?” Cancer Epidemiology, Biomarkers and Prevention, Vol. 13, No. 11, 2004, pp. 1765-1771.
[23] A. W. Hsing, I, Y.-T. Gao, G. Wu, X. Wang, J. Deng, Y.-L. Chen, I. A. Sesterhenn, F. K. Mostofi, J. Benichou and C. Chang, “Polymorphic CAG and GGN Repeat Lengths in the Androgen Receptor Gene and Prostate Cancer Risk: A Population-based Case-Control Study in China,” Cancer Research, Vol. 60, No. 18, 2000, pp. 5111-5116.
[24] A. Khattri, R. K. Pandey, N. J. Gupta, B. Chakravarty, M. Deendayal, L. Singh and K. Thangaraj, “CA Repeat and RsaI Polymorphisms in ERb Gene Are Not Associated with Infertility in Indian Men,” International Journal of Andrology, Vol. 32, No. 1, 2007, pp. 1365-2605.
[25] R. A. Kittles, D. Young, S. Weinrich, et al., “Extent of Linkage Disequilibrium between the Androgen Receptor Gene CAG and GGC Repeats in Human Populations: Implications for Prostate Cancer Risk,” Human Genetics, Vol. 109, No. 3, 2001, pp. 253-261. doi:10.1007/s004390100576
[26] M. Sasaki, M. Kaneuchi, N. Sakuragi, S. Fujimoto, P. R. Carroll and R. Dahiya, “The polyglycine and Polyglutamine Repeats in the Androgen Receptor Gene in Japanese and Caucasian Populations,” Biochemical and Biophysical Research Communications, Vol. 312, No. 4, 2003, pp. 1244-1247. doi:10.1016/j.bbrc.2003.11.075
[27] N. M. Suter, K. E. Malone, J. R. Darling, D. R. Doody and E. A. Ostrander, “Androgen Receptor (CAG)n and (GGC)n Polymorphisms and BC Risk in a Population-Based Case-Control Study of Young Women,” Cancer Epidemiology, Biomarkers & Prevention, Vol. 12, No. 2, 2003, pp. 127-135.
[28] Y. J. Hao, R. Montiel, B. H. Li, E. Y. Huang, L. Zeng and Y. S. Huang, “Association between Androgen Receptor Gene CAG Repeat Polymorphism and Breast Cancer Risk: A Meta-Analysis,” Breast Cancer Research and Treatment, Vol. 124, No. 3, 2010, pp. 815-820.
[29] Z. Nawaz and B. W. O’Malley, “Urban Renewal in the Nucleus: Is Protein Turnover by Proteasomes Absolutely Required for Nuclear Receptor Regulated Transcription?” Molecular Endocrinology, Vol. 18, No. 3, 2004, pp. 493-499. doi:10.1210/me.2003-0388
[30] H. Yu, B. Bharaj, E. J. Vassilikos, M. Giai and E. P. Diamandis, “Shorter CAG Repeat Length in the Androgen Receptor Gene Is Associated with More Aggressive Forms of Breast Cancer,” Breast Cancer Research and Treatment, Vol. 59, No. 2, 2000, pp. 153-161. doi:10.1023/A:1006356502820

Copyright © 2024 by authors and Scientific Research Publishing Inc.

Creative Commons License

This work and the related PDF file are licensed under a Creative Commons Attribution 4.0 International License.